PTC Therapeutics (PTCT) Director Schmertzler Sells $679K of Stock
Key Points
- Director Michael Schmertzler sold 10,000 shares of PTC Therapeutics, Inc. (PTCT) at an average price of $67.85 per share for a total value of $678,533 on September 17, 2026.
- The stock traded around $59.22 recently, down about 12.9% from its close of $68.00 on the transaction date.
- PTC Therapeutics posts trailing twelve month revenue of $1.01 billion and looks toward its next earnings update on October 29, 2026.
Since the trade, $PTCT is down 8.4% after 1 week, down 11.3% after 1 month and down 11.3% to date (from the $68 close on Sep 17, 2026).
Get PTC Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $PTCT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated PTC Therapeutics, Inc. alert may contain errors. Disclosures
Director Michael Schmertzler sold 10,000 shares of PTC Therapeutics, Inc. (PTCT) on September 17, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
PTCT
PTC Therapeutics, Inc.
Inside Michael Schmertzler's PTCT Trade
Schmertzler parted with the 10,000 shares at a price of $67.85 per share, bringing the total value of the sale to $678,533. The company's stock closed at $68.00 on the day of the transaction.
Other Institutional Activity in PTC Therapeutics
Institutional investors have adjusted their holdings in the firm recently. RTW Investments LP held 7,746,415 shares valued at $458,897,637. Jupiter Topco LLC added 3,618,201 shares, ending with 7,236,402 shares worth about $428,684,466. Meanwhile, Burney Co. cut its entire position, selling 37,320 shares.
PTC Therapeutics, Inc. Stock Down 2.9%
The shares recently traded around $59.22, sitting about 12.9% below their $68.00 close on the trade date. The stock has a market capitalization of roughly $4.94 billion and operates with a forward P/E ratio of roughly 25.0.
Recent Earnings
The biopharmaceutical company reported trailing twelve month revenue of $1.01 billion alongside an EPS of -$0.62. Revenue grew 101.5% over the prior year, while the net margin stood at -3.8%. The company is scheduled to release its next financial results on October 29, 2026.
Insider Buying and Selling at PTC Therapeutics, Inc.
Executive and insider transactions have continued around the firm. Chief Technical Ops Officer Neil Gregory Almstead completed several trades earlier in the year, including buying 5,323 shares at $38.10 on June 24 and selling 5,323 shares at $85.03 on the same date, followed by additional transactions in late June.
Analysts Set New Price Targets
Wall Street firms have updated their outlooks on the stock. Wells Fargo maintained an Overweight rating while adjusting its price target to $93.00 on July 20, and later raised it to $109.00 on August 13. Morgan Stanley maintained an Overweight rating with a $104.00 target on July 31, while Barclays maintained an Overweight rating with a $122.00 target on August 14. Analysts hold a consensus buy rating on the stock with a mean price target of $100.33.
About PTC Therapeutics
Headquartered in Warren, New Jersey, PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare disorders affecting children and adults. The organization employs 991 people and advances therapies across global markets.
Bottom Line
Insiders continue to execute scheduled sales as the company approaches its late October earnings report. Investors will be watching the upcoming financial results for further updates on revenue growth and clinical progress.
Related Filing Alerts
Source: Michael Schmertzler's Form 4 filing on $PTCT (Sep 17, 2026). Written by software, not financial advice. How we make alerts